Drug updated on 4/16/2024
| Dosage Form | Tablet (oral: 2.5 mg, 5 mg, 10 mg, 20 mg) |
| Drug Class | Beta-adrenergic blocking agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Summary
- Nebivolol (Bystolic) is indicated for the treatment of hypertension, with its primary function being to lower blood pressure and reduce the risk of fatal and nonfatal cardiovascular events such as strokes and myocardial infarctions.
- Two systematic reviews/meta-analyses were reviewed which provided insights into nebivolol's efficacy in treating hypertensive disease compared to other antihypertensive drugs.
- The first study included a population of 12,465 patients with systemic arterial hypertension aged between 18-85 years; approximately 17% were Black ethnicity, around 55% were men, and nearly 10% had diabetes.
- In terms of systolic blood pressure management, nebivolol was found superior to other β-blockers and diuretics but showed no difference when compared with angiotensin receptor blockers or calcium channel blockers according to the first document.
- For diastolic blood pressure control, nebivolol proved more efficient than other β-blockers, angiotensin receptor blockers, diuretics as well as calcium channel blockers based on findings from the same review.
- The second meta-analysis concluded that there was no significant difference between nebivolol and other second-generation β-blockers in reducing both systolic & diastolic blood pressures; however it highlighted better tolerability for Bystolic due to a stable heart rate & lower risk of adverse events compared with these alternatives.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Bystolic (nebivolol) Prescribing Information. | 2023 | Allergan USA, Inc. Madison, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Nebivolol for the treatment of essential systemic arterial hypertension: a systematic review and meta-analysis. | 2020 | American Journal of Cardiovascular Drugs |
| Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials. | 2020 | Journal of International Medical Research |